KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Inovio Pharmaceuticals (INO) Convertible Debt (2019 - 2022)

Historic Convertible Debt for Inovio Pharmaceuticals (INO) over the last 4 years, with Q4 2022 value amounting to $16.6 million.

  • Inovio Pharmaceuticals' Convertible Debt rose 1106.44% to $16.6 million in Q4 2022 from the same period last year, while for Dec 2022 it was $16.6 million, marking a year-over-year increase of 1106.44%. This contributed to the annual value of $16.6 million for FY2022, which is 1106.44% up from last year.
  • Per Inovio Pharmaceuticals' latest filing, its Convertible Debt stood at $16.6 million for Q4 2022, which was up 1106.44% from $16.3 million recorded in Q3 2022.
  • Over the past 5 years, Inovio Pharmaceuticals' Convertible Debt peaked at $65.8 million during Q2 2020, and registered a low of $14.1 million during Q1 2021.
  • For the 4-year period, Inovio Pharmaceuticals' Convertible Debt averaged around $31.7 million, with its median value being $16.4 million (2022).
  • Per our database at Business Quant, Inovio Pharmaceuticals' Convertible Debt plummeted by 7796.83% in 2020 and then skyrocketed by 1519.68% in 2022.
  • Over the past 4 years, Inovio Pharmaceuticals' Convertible Debt (Quarter) stood at $64.2 million in 2019, then plummeted by 77.97% to $14.1 million in 2020, then grew by 5.8% to $15.0 million in 2021, then rose by 11.06% to $16.6 million in 2022.
  • Its Convertible Debt was $16.6 million in Q4 2022, compared to $16.3 million in Q3 2022 and $16.5 million in Q2 2022.